๐ Daily ETF Overview
Across the Ark Invest universe, ARKG has been the clear laggard.
While the flagship ARKK ETF has been consistently making new highs in this environment, ARKG has spent the year stuck in the mud.
Thatโs changing.
On our thematic dashboard, Genomics has flipped from red to green. And itโs not happening in a vacuum โ the entire biotech complex has been quietly ripping higher.
Weโre seeing major breakouts in one of the highest-beta industries in the market.
With this kind of momentum at their backs, Genomics and biotech look like one of the most compelling risk-on areas into year-end.